Description
Contact hours available until 4/16/2016.
Requirements for Successful Completion:
Complete the learning activity in its entirety and complete the online CNE evaluation.
Speaker, Faculty, Planners and Authors Conflict of Interest Disclosure:
Speaker(s) have no disclosures to declare.
Planning Committee:
• Annette Hood discloses that she is a member of the Amgen speakers’ bureau.
• Denise Murcek discloses other financial/material support as an employee of the VA Medical Center.
• Elizabeth St. John discloses other financial/material support as an employee of Fresenius Medical Care.
• Kyra Trappett discloses other financial/material support as an employee of DaVita.
Commercial Support and Sponsorship:
No commercial support or sponsorship declared.
Accreditation Statement:
American Nephrology Nurses’ Association is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
ANNA is a provider approved by the California Board of Registered Nursing, provider number CEP 00910.
Objectives:
• Review the epidemiologic association of uric acid and progression of CKD and CVD.
• Discuss the mechanisms by which uric acid causes vascular damage.
• Determine why patients with CKD have elevated uric acid.
• Analyze clinic trial data on the efficacy of uric acid lowering therapy to treat or prevent hypertension, CKD, and cardiovascular disease.
Speaker(s):
